La Jolla Pharmaceutical Company (LJPC) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The companys major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its clinical-stage investigational product includes LJPC-401, a formulation of synthetic human hepcidin intended for the treatment of iron overload, such as hereditary hemochromatosis, sickle cell disease, beta thalassemia and myelodysplastic syndrome. The company distributes its products through a network of specialty distributors to hospitals across the US. La Jolla is headquartered in San Diego, California, the US.

La Jolla Pharmaceutical Company (LJPC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 5
List of Figures 5
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 11
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 14
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 15
Licensing Agreements 16
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 16
IURTC Enters into Licensing Agreement with La Jolla Pharma 17
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 18
La Jolla Pharma Enters into Licensing Agreement with George Washington University 19
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 20
Equity Offering 21
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharmaceutical Company - Key Competitors 30
La Jolla Pharmaceutical Company - Key Employees 31
La Jolla Pharmaceutical Company - Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
May 10, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress 33
Feb 22, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress 35
Oct 26, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 36
Jul 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 37
Apr 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 38
Feb 23, 2017: La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress 39
Product News 40
09/13/2017: Researchers Develop New Strategy to Target KRAS Mutant Cancer 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List Of Tables

List of Tables
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 11
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 14
La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 15
La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 16
IURTC Enters into Licensing Agreement with La Jolla Pharma 17
IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 18
La Jolla Pharma Enters into Licensing Agreement with George Washington University 19
La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 20
La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21
La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23
La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24
La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26
La Jolla Pharma Completes Private Placement Of Shares For US$6.7 Million 28
La Jolla Pharma Completes Private Placement Of Preferred Stock For US$3.3 Million 29
La Jolla Pharmaceutical Company, Key Competitors 30
La Jolla Pharmaceutical Company, Key Employees 31
La Jolla Pharmaceutical Company, Subsidiaries 32

List Of Figures

List of Figures
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 11

Constellation Pharmaceuticals Inc (CNST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal

USD 250 View Report

Integral Molecular Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Integral Molecular Inc (Integral Molecular) is a biotechnology company that provides therapeutic solutions. The company offers technologies and therapeutic antibodies for under exploited membrane protein targets. It provides lipoparticle, shotgun

USD 250 View Report

La Jolla Pharmaceutical Company Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

La Jolla Pharmaceutical Company Company Profile is a detailed strategic and analytical report on La Jolla Pharmaceutical Company. The 2018 version of the report offers detailed insights into the companys

USD 200 View Report

La Jolla Institute for Allergy & Immunology - Pharmaceuticals & Healthcare - Deals and Alliances Profile

La Jolla Institute for Allergy & Immunology (LIAI) is a biomedical research institute that offers solutions for infectious agents and cancers. The institute provides research on prevention, treatment, and cure

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available